PPT-Module 9: HER2-Positive and Triple-Negative BC

Percent with Patients Number of Patients Median ERpositive HER2negative breast cancer for whom you ordered a genomic assay 92 14 Metastatic ERpositive HER2negative breast cancer 96 10. 1 Positive Negative Actual Positive A: True Positive Negative Negative C: False Positive D: True Negative BAA Accuracy (AC):: is the proportion of the total number ofpredictions that wer Lauren Barney. April 17, 2013. Breast Cancer Subtypes. Breast cancer is classified into clinical subtypes based upon receptor expression. These subtypes dictate possible therapeutic options and vary in their prognosis. First . Line and Beyond. Moderator:. Joseph Gligorov, MD, . PhD . Head, Cancer . Coordination Center . HUEP. University . Cancer . Institute. Sorbonne University. Paris. , . France. Panelist:. Carlos H. Barrios, . Lauren Barney. April 17, 2013. Breast Cancer Subtypes. Breast cancer is classified into clinical subtypes based upon receptor expression. These subtypes dictate possible therapeutic options and vary in their prognosis. ASCO-CAP Recommendations For HER2 Testing in Breast Cancer. Criteria For Reporting HER2 Test Results . as Positive. Criteria for Reporting HER2 Test Results . as Negative. Criteria for Reporting Equivocal Results . What’s Positive about Triple Negative Breast Cancer ? Julie R. Gralow, M.D. Jill Professor Endowed Professor of Breast Cancer Director, Breast Medical Oncology Seattle Cancer Care Alliance University of Washington School of Medicine Contents PageIntended Use 4Summary and Explanation -Breast 5Background 5Characteristics 5Principle of Procedure -Breast 5Reagents -Breast 6Materials provided 6Materials required but not provided 7Stor Triple-Negative Breast Cancer. Jamie Carroll, APRN, MSN, CNP. Hope S . Rugo. , MD. . Disclosures for . Ms. Carroll. No financial interests or affiliations to disclose. Disclosures for Dr . Rugo. Contracted Research. Lauren Barney. April 17, 2013. Breast Cancer Subtypes. Breast cancer is classified into clinical subtypes based upon receptor expression. These subtypes dictate possible therapeutic options and vary in their prognosis. A. University of Tennessee Medical Center – Knoxville. Departments of Pathology, Surgery, and Medicine. BREAST CANCER IN YOUNG AGE (≤40 YEARS): THE UNIVERSITY OF. . TENNESSEE MEDICAL CENTER AT KNOXVILLE 10 YEAR EXPERIENCE. Luminal B-like (HER2-positive):!ER-positive!HER2-positive!Any Ki67 ** Aggressive phenotypes: TNBC or HER2-positive breast cancer!If ChTis planned, it should all be given as neoadjuvant"Concomitant pos Breast Cancer . Elizabeth O’Reilly, MSN, MPH, ANP-BC. Sara . Hurvitz. , MD. Disclosures for . Ms. O’Reilly. No financial interests or affiliations to disclose. Disclosures for Dr . Hurvitz. Salary: . Bidstrup. Mrs B is a 49 . yo. woman who attended for a regular 3 weekly review and Herceptin dose. Intro. Dec 2000: . attended GP regarding lump that had been present in L) breast for 6/12. . Bx. - breast ca. breast. . cancer. . needs. . different. . therapeutic. . strategies. . than. HER-2 . enriched. . tumors. ?. Patrizia Vici. Cleopatra. TDM-1: . EMILIA. Verma. S ESMO 2012. (. Activity. . HR+.